{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:58Z","timestamp":1792783378233,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Aksaray University","id":[{"id":"https:\/\/ror.org\/026db3d50","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is characterized by microvascular injury and progressive fibrosis leading to respiratory impairment. This study aimed to evaluate the effect of anti-fibrotic therapy on intercostal and diaphragmatic shear wave elastography (SWE) measurements in patients with SSc-ILD and to assess their relationship with pulmonary function tests and Borg dyspnea scores. 30 patients with SSc-ILD receiving stable background therapy and 30 healthy controls were evaluated prospectively between January and August 2025. Intercostal and diaphragmatic SWE, pulmonary function tests, and Borg dyspnea scores were obtained before and three months after initiation of anti-fibrotic therapy. At three months, SSc-ILD patients showed significant improvement in FVC and FEV\u2081 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.009 and\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02), while Borg scores and intercostal and diaphragmatic SWE values decreased (all\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Elastography measurements regressed to levels comparable with controls. Changes in intercostal SWE correlated with \u0394FVC and \u0394FEV\u2081 (\n                    <jats:italic>R<\/jats:italic>\n                    \u2009=\u2009\u20130.769,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001 and\n                    <jats:italic>R<\/jats:italic>\n                    \u2009=\u2009\u20130.492,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.007), and \u0394Borg correlated with both intercostal and diaphragmatic SWE (\n                    <jats:italic>R<\/jats:italic>\n                    \u2009=\u20090.89 and\n                    <jats:italic>R<\/jats:italic>\n                    \u2009=\u20090.793, both\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). In multivariable analysis, elastographic improvement was the strongest determinant of dyspnea reduction (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Anti-fibrotic therapy initiation was associated with early reductions in respiratory muscle elastographic stiffness parameters and dyspnea in SSc-ILD. These short-term changes may reflect early biomechanical or functional alterations rather than definitive structural remodeling.\n                  <\/jats:p>","DOI":"10.1007\/s11739-026-04388-w","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:50:37Z","timestamp":1779123037000},"page":"2099-2108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early effects of antifibrotic therapy on respiratory muscle stiffness and dyspnea in SSc-ILD: a shear wave elastography study"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-1462","authenticated-orcid":false,"given":"Bu\u011fra","family":"Kerget","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130smail","family":"\u00c7\u0131nar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen Saba","family":"\u00d6ktem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aynur","family":"Da\u015fdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0131rma Merve","family":"\u00c7etin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Ye\u015filyurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alperen","family":"Aksakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Alper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"10103","key":"4388_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390(10103):1685\u20131699. https:\/\/doi.org\/10.1016\/S0140-6736(17)30933-9","journal-title":"Lancet"},{"issue":"4","key":"4388_CR2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","volume":"19","author":"JE Pope","year":"2023","unstructured":"Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T (2023) State-of-the-art evidence in the treatment of systemic sclerosis. Nat Rev Rheumatol 19(4):212\u2013226. https:\/\/doi.org\/10.1038\/s41584-023-00909-5","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"4388_CR3","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1093\/rheumatology\/kead491","volume":"63","author":"K Morrisroe","year":"2024","unstructured":"Morrisroe K, Hansen D, Stevens W, Ross L, Sahhar J, Ngian G-S et al (2024) Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis-related interstitial lung disease. Rheumatology 63(7):1874\u20131881. https:\/\/doi.org\/10.1093\/rheumatology\/kead491","journal-title":"Rheumatology"},{"issue":"12","key":"4388_CR4","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/ard-2022-222564","volume":"81","author":"Y Allanore","year":"2022","unstructured":"Allanore Y, Vonk MC, Distler O, Azuma A, Mayes MD, Gahlemann M et al (2022) Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. Ann Rheum Dis 81(12):1722\u20131729. https:\/\/doi.org\/10.1136\/ard-2022-222564","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4388_CR5","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/rheumatology\/keac535","volume":"62","author":"CP Denton","year":"2023","unstructured":"Denton CP, Goh NS, Humphries SM, Maher TM, Spiera R, Devaraj A et al (2023) Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial. Rheumatology 62(5):1870\u20131876. https:\/\/doi.org\/10.1093\/rheumatology\/keac535","journal-title":"Rheumatology"},{"issue":"1","key":"4388_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","volume":"84","author":"F Del Galdo","year":"2025","unstructured":"Del Galdo F, Lescoat A, Conaghan PG, Bertoldo E, \u010coli\u0107 J, Santiago T et al (2025) EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 84(1):29\u201340. https:\/\/doi.org\/10.1136\/ard-2024-226430","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4388_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","volume":"209","author":"G Raghu","year":"2024","unstructured":"Raghu G, Montesi SB, Silver RM, Hossain T, Macrea M, Herman D et al (2024) Treatment of systemic sclerosis\u2013associated interstitial lung disease: evidence-based recommendations. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 209(2):137\u2013152. https:\/\/doi.org\/10.1164\/rccm.202306-1113ST","journal-title":"Am J Respir Crit Care Med"},{"key":"4388_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.08.021","author":"KM Antoniou","year":"2025","unstructured":"Antoniou KM, Distler O, Gheorghiu A-M, Moor CC, Vikse J, Bizymi N et al (2025) ERS\/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease. Ann Rheum Dis. https:\/\/doi.org\/10.1016\/j.ard.2025.08.021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4388_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","volume":"9","author":"KB Highland","year":"2021","unstructured":"Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A et al (2021) Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med 9(1):96\u2013106. https:\/\/doi.org\/10.1016\/S2213-2600(20)30330-1","journal-title":"Lancet Respir Med"},{"key":"4388_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000001111","author":"A Lescoat","year":"2025","unstructured":"Lescoat A, Chen YT, Khanna D (2025) Patient-reported outcomes in systemic sclerosis: insights into quality of life and disease burden. Curr Opin Rheumatol. https:\/\/doi.org\/10.1097\/BOR.0000000000001111","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"4388_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-019-2486-3","volume":"20","author":"C Zhou","year":"2019","unstructured":"Zhou C, Zeldin Y, Baratz ME, Kathju S, Satish L (2019) Investigating the effects of pirfenidone on TGF-\u03b21 stimulated non-SMAD signaling pathways in Dupuytren\u2019s disease-derived fibroblasts. BMC Musculoskelet Disord 20(1):135. https:\/\/doi.org\/10.1186\/s12891-019-2486-3","journal-title":"BMC Musculoskelet Disord"},{"issue":"10","key":"4388_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102629","volume":"10","author":"J Alonso-P\u00e9rez","year":"2022","unstructured":"Alonso-P\u00e9rez J, Carrasco-Rozas A, Borrell-Pages M, Fern\u00e1ndez-Sim\u00f3n E, Pi\u00f1ol-Jurado P, Badimon L et al (2022) Nintedanib reduces muscle fibrosis and improves muscle function of the alpha-sarcoglycan-deficient mice. Biomedicines 10(10):2629. https:\/\/doi.org\/10.3390\/biomedicines10102629","journal-title":"Biomedicines"},{"issue":"12","key":"4388_CR13","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","volume":"15","author":"SA Guler","year":"2018","unstructured":"Guler SA, Winstone TA, Murphy D, Hague C, Soon J, Sulaiman N et al (2018) Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression. Ann Am Thorac Soc 15(12):1427\u20131433. https:\/\/doi.org\/10.1513\/AnnalsATS.201806-362OC","journal-title":"Ann Am Thorac Soc"},{"issue":"suppl_5","key":"4388_CR14","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/rheumatology\/kex196","volume":"56","author":"UA Walker","year":"2017","unstructured":"Walker UA, Clements PJ, Allanore Y, Distler O, Oddis CV, Khanna D et al (2017) Muscle involvement in systemic sclerosis: points to consider in clinical trials. Rheumatology 56(suppl_5):v38\u2013v44. https:\/\/doi.org\/10.1093\/rheumatology\/kex196","journal-title":"Rheumatology"},{"issue":"11","key":"4388_CR15","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1093\/rheumatology\/keac091","volume":"61","author":"ER Volkmann","year":"2022","unstructured":"Volkmann ER, Kreuter M, Hoffmann-Vold AM, Wijsenbeek M, Smith V, Khanna D et al (2022) Dyspnoea and cough in patients with systemic sclerosis\u2013associated interstitial lung disease in the SENSCIS trial. Rheumatology 61(11):4397\u20134408. https:\/\/doi.org\/10.1093\/rheumatology\/keac091","journal-title":"Rheumatology"},{"issue":"1","key":"4388_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12931-020-01524-8","volume":"21","author":"T Veit","year":"2020","unstructured":"Veit T, Barnikel M, Crispin A, Kneidinger N, Ceelen F, Arnold P et al (2020) Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study. Respir Res 21(1):270. https:\/\/doi.org\/10.1186\/s12931-020-01524-8","journal-title":"Respir Res"},{"issue":"4","key":"4388_CR17","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1378\/chest.123.4.1082","volume":"123","author":"NM Punjabi","year":"2003","unstructured":"Punjabi NM, Shade D, Patel AM, Wise RA (2003) Measurement variability in single-breath diffusing capacity of the lung. Chest 123(4):1082\u20131089. https:\/\/doi.org\/10.1378\/chest.123.4.1082","journal-title":"Chest"},{"issue":"1","key":"4388_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/ard-2024-226429","volume":"84","author":"A Lescoat","year":"2025","unstructured":"Lescoat A, Bertoldo E, \u010coli\u0107 J, Santiago T, Suliman YA, Emmel J et al (2025) Results from the international collaborative systematic literature review informing the 2023 EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 84(1):77\u201392. https:\/\/doi.org\/10.1136\/ard-2024-226429","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4388_CR19","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","volume":"200","author":"BL Graham","year":"2019","unstructured":"Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL et al (2019) Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 200(8):e70\u2013e88","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"4388_CR20","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","volume":"2","author":"A-M Hoffmann-Vold","year":"2020","unstructured":"Hoffmann-Vold A-M, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsotti S et al (2020) The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. The Lancet Rheumatol 2(2):e71\u2013e83. https:\/\/doi.org\/10.1016\/S2665-9913(19)30144-4","journal-title":"The Lancet Rheumatol"},{"issue":"11","key":"4388_CR21","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1093\/rheumatology\/keae394","volume":"63","author":"CP Denton","year":"2024","unstructured":"Denton CP, De Lorenzis E, Roblin E, Goldman N, Alcacer-Pitarch B, Blamont E et al (2024) The 2024 British Society for Rheumatology guideline for management of systemic sclerosis. Rheumatology 63(11):2956\u20132975. https:\/\/doi.org\/10.1093\/rheumatology\/keae394","journal-title":"Rheumatology"},{"issue":"1","key":"4388_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/23971983188169","volume":"4","author":"ER Volkmann","year":"2019","unstructured":"Volkmann ER, Tashkin DP, Sim M, Kim GH, Goldin J, Clements PJ (2019) Determining progression of scleroderma-related interstitial lung disease. J of Scleroderma and Relat Disord 4(1):62\u201370. https:\/\/doi.org\/10.1177\/23971983188169","journal-title":"J of Scleroderma and Relat Disord"},{"issue":"6","key":"4388_CR23","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00401-021-02305-3","volume":"141","author":"E Siegert","year":"2021","unstructured":"Siegert E, Uruha A, Goebel H-H, Preu\u00dfe C, Casteleyn V, Kleefeld F et al (2021) Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology. Acta Neuropathol 141(6):917\u2013927","journal-title":"Acta Neuropathol"},{"issue":"2","key":"4388_CR24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.berh.2008.01.008","volume":"22","author":"SB Randone","year":"2008","unstructured":"Randone SB, Guiducci S, Cerinic MM (2008) Musculoskeletal involvement in systemic sclerosis. Best Pract Res Clin Rheumatol 22(2):339\u2013350. https:\/\/doi.org\/10.1016\/j.berh.2008.01.008","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"5","key":"4388_CR25","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/ard.2007.075721","volume":"67","author":"M Baron","year":"2008","unstructured":"Baron M, Sutton E, Hudson M, Thombs B, Markland J, Pope J et al (2008) The relationship of dyspnoea to function and quality of life in systemic sclerosis. Ann Rheum Dis 67(5):644\u2013650. https:\/\/doi.org\/10.1136\/ard.2007.075721","journal-title":"Ann Rheum Dis"},{"issue":"2_suppl","key":"4388_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/239719832090417","volume":"5","author":"LA Saketkoo","year":"2020","unstructured":"Saketkoo LA, Scholand MB, Lammi MR, Russell A-M (2020) Patient-reported outcome measures in systemic sclerosis\u2013related interstitial lung disease for clinical practice and clinical trials. J Scleroderma Relat Disord 5(2_suppl):48\u201360. https:\/\/doi.org\/10.1177\/239719832090417","journal-title":"J Scleroderma Relat Disord"},{"key":"4388_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.lfs.2015.12.015","volume":"145","author":"S Zanotti","year":"2016","unstructured":"Zanotti S, Bragato C, Zucchella A, Maggi L, Mantegazza R, Morandi L et al (2016) Anti-fibrotic effect of pirfenidone in muscle derived-fibroblasts from Duchenne muscular dystrophy patients. Life Sci 145:127\u2013136. https:\/\/doi.org\/10.1016\/j.lfs.2015.12.015","journal-title":"Life Sci"},{"issue":"7","key":"4388_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0792-6","volume":"9","author":"P Pi\u00f1ol-Jurado","year":"2018","unstructured":"Pi\u00f1ol-Jurado P, Su\u00e1rez-Calvet X, Fern\u00e1ndez-Sim\u00f3n E, Gallardo E, De La Oliva N, Mart\u00ednez-Muriana A et al (2018) Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy. Cell Death Dis 9(7):776. https:\/\/doi.org\/10.1038\/s41419-018-0792-6","journal-title":"Cell Death Dis"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04388-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04388-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04388-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:33:59Z","timestamp":1789540439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-026-04388-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4388"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04388-w","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"28 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest to the publication of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the study was obtained from the Ataturk University Faculty of Medicine Ethics Committee (B.30.2.ATA.0.01.00\/632). This research was carried out in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}